Renovar Incorporated Presents Data On New Kidney Diagnostic At American Transplant Congress
10/19/2005 5:09:48 PM
MADISON, Wis.--(BUSINESS WIRE)--May 25, 2005--Renovar, Inc., an in vitro diagnostics company, announced results of its new test for kidney transplant patients, at the American Transplantation Congress in Seattle, Washington. The meeting is the Joint Annual Meeting of the American Societies of Transplant Surgeons and Transplantation.
The results, presented by Huaizhong Hu, Ph.D., a scientist at the University of Wisconsin and at Renovar, were part of a study conducted by Renovar at the University of Wisconsin-Madison, Division of Transplantation. The Renovar assay, currently under development, is intended to monitor kidney function in transplant patients, based on the identification of key biomarkers in urine. The biomarkers are cytokines, small secreted proteins which mediate and regulate immunity, inflammation and the formation of blood cells.